Data presented at the 2025 Crohn’s and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company ...

For older adults with inflammatory bowel disease (IBD), there was no significant difference in the risk of major ...

Data presented at the 2025 Crohn's and Colitis Congress PALI-2108 demonstrated to effectively reduce colitis symptoms in DSS mouse model without CNS toxicity associated with systemic exposure Company ...

JACK FITZWATER has revealed how he thought his football career was in jeopardy when he was forced to visit the toilet 40 times a day. The defender hopes to help League One club Exeter topple ...

A preliminary modeling study suggests that four variables accessible at discharge could predict the risk for 90-day ...

Clinical trials help researchers studying chronic conditions answer important questions about the diseases and their treatment options. However, uncertainty about what to expect and a lack of ...

Palisade Bio (PALI) announced the presentation of positive preclinical data from PALI-2108, an orally administered, colon-specific ...

Eli Lilly has announced results from the VIVID-2 open-label extension study, showing that most patients with moderately to ...

Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress: Indianapolis Monday, February 10, 20 ...

While the rising incidence is due in part to environmental factors including ultra-processed foods and smoking, the ...

Synedgen, Inc., a biotechnology company targeting human glycobiology to treat gastrointestinal diseases, today announced the appointment of Dr. Laura Saward, PhD, as the company's Chief Scientific ...

No significant difference in the risk for MACE was observed between patients with IBD receiving JAK vs TNF inhibitors.